11 papers this month, including an announcement that naloxone is now over-the-counter in Australia.
Evans TI, Hadland SE,
Clark MA, Green TC, Marshall BD.
Harm Reduct J. 2016 Jul
26;13(1):24. doi: 10.1186/s12954-016-0113-2.
Comments: Less than half
knew about it.
Stein MD, Kanabar M,
Anderson BJ, Lembke A, Bailey GL.
J Subst Abuse Treat.
2016 Sep;68:57-61. doi: 10.1016/j.jsat.2016.06.008. Epub 2016 Jun 16.
Comments: Important
work, as there’s an effort to also reduce benzodiazepine prescribing among
people who are on opioids. Understanding the drivers of BDZ use should be
helpful in structuring interventions. Anxiety and managing opioid withdrawal
were two main reasons.
Jones CM, Baldwin GT,
Manocchio T, White JO, Mack KA.
MMWR Morb Mortal Wkly
Rep. 2016 Jul 8;65(26):667-71. doi: 10.15585/mmwr.mm6526a2.
Comments: Interesting
analysis of methadone prescribing, overdose, and diversion. It seems that
efforts to reduce methadone, beginning in 2006, corresponded with reduced
diversion and overdose; unfortunate that opioid overdose death overall
continued to escalate.
Makarenko I, Mazhnaya A,
Polonsky M, Marcus R, Bojko MJ, Filippovych S, Springer S, Dvoriak S, Altice
FL.
Drug Alcohol Depend.
2016 Aug 1;165:213-20. doi: 10.1016/j.drugalcdep.2016.06.011. Epub 2016 Jun 17.
Comments: Barriers to
enrolling in agonist treatment in Ukraine.
5) The next three letters were responding to an earlier paper from several months ago regarding intranasal naloxone:
Coffin P, Rich J, Dailey M, Stancliff S, Beletsky L.
Addiction. 2016 Jul 14. doi: 10.1111/add.13412. [Epub ahead of print] No abstract available.
Doe-Simkins M, Banta-Green C, Davis CS, Green TC, Walley AY.
Addiction. 2016 Jul 14. doi: 10.1111/add.13399. [Epub ahead of print] No abstract available.
Strang J, Mcdonald R.
Addiction. 2016 Jul 13. doi: 10.1111/add.13468. [Epub ahead of print] No abstract available.
Nielsen S, Larance B,
Degenhardt L, Gowing L, Kehler C, Lintzeris N.
Cochrane Database Syst
Rev. 2016 May 9;(5):CD011117. doi: 10.1002/14651858.CD011117.pub2. Review.
Comment: Low to moderate
evidence to support this intervention, but it appears more effective than other
options.
Erbas B, Arnold M.
MMW Fortschr Med. 2016
Feb 18;158(3):54-6. doi: 10.1007/s15006-016-7821-0. Review. German. No abstract
available.
Comments: Can’t access.
Lenton SR, Dietze PM,
Jauncey M.
Med J Aust. 2016 Mar
7;204(4):146-7. No abstract available.
Comments: In Australia
this means it is now available for over-the-counter purchase!
Kirwan A, Curtis M, van
Beek IA, Cantwell K, Dietze PM.
Med J Aust. 2016 Mar
7;204(4):143. No abstract available.
Comments: Can’t access.
Jones CM, Lurie PG,
Compton WM.
Am J Public Health. 2016
Apr;106(4):689-90. doi: 10.2105/AJPH.2016.303062. Epub 2016 Feb 18.
Comments: 1170% increase
in naloxone dispensed from US retail pharmacies from 2013-2015. Not sure the
actual numbers because I can’t access the article.
Herzberg D, Guarino H,
Mateu-Gelabert P, Bennett AS.
Am J Public Health. 2016
Mar;106(3):408-10. doi: 10.2105/AJPH.2015.302982. Epub 2016 Jan 21.
Comments: Fascinating
take. And timely, as we’ve already started seeing some – albeit still spotty – policy
movements away from the calls for humane treatment in the current opioid
epidemic in the U.S.
No comments:
Post a Comment